GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OrbusNeich Medical Group Holdings Ltd (HKSE:06929) » Definitions » Cash Flow from Financing

OrbusNeich Medical Group Holdings (HKSE:06929) Cash Flow from Financing : HK$-77 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is OrbusNeich Medical Group Holdings Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2024, OrbusNeich Medical Group Holdings paid HK$6 Mil more to buy back shares than it received from issuing new shares. It received HK$0 Mil from issuing more debt. It paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent HK$83 Mil paying cash dividends to shareholders. It spent HK$1 Mil on other financial activities. In all, OrbusNeich Medical Group Holdings spent HK$90 Mil on financial activities for the six months ended in Jun. 2024.


OrbusNeich Medical Group Holdings Cash Flow from Financing Historical Data

The historical data trend for OrbusNeich Medical Group Holdings's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OrbusNeich Medical Group Holdings Cash Flow from Financing Chart

OrbusNeich Medical Group Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial -3.67 1,141.06 447.23 6.90 -

OrbusNeich Medical Group Holdings Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only 453.86 -13.33 20.20 -96.91 -

OrbusNeich Medical Group Holdings Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

OrbusNeich Medical Group Holdings's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

OrbusNeich Medical Group Holdings's Cash from Financing for the quarter that ended in Jun. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OrbusNeich Medical Group Holdings  (HKSE:06929) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

OrbusNeich Medical Group Holdings's issuance of stock for the six months ended in Jun. 2024 was HK$0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

OrbusNeich Medical Group Holdings's repurchase of stock for the six months ended in Jun. 2024 was HK$-6 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

OrbusNeich Medical Group Holdings's net issuance of debt for the six months ended in Jun. 2024 was HK$0 Mil. OrbusNeich Medical Group Holdings received HK$0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

OrbusNeich Medical Group Holdings's net issuance of preferred for the six months ended in Jun. 2024 was HK$0 Mil. OrbusNeich Medical Group Holdings paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

OrbusNeich Medical Group Holdings's cash flow for dividends for the six months ended in Jun. 2024 was HK$-83 Mil. OrbusNeich Medical Group Holdings spent HK$83 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

OrbusNeich Medical Group Holdings's other financing for the six months ended in Jun. 2024 was HK$-1 Mil. OrbusNeich Medical Group Holdings spent HK$1 Mil on other financial activities.


OrbusNeich Medical Group Holdings Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of OrbusNeich Medical Group Holdings's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


OrbusNeich Medical Group Holdings Business Description

Traded in Other Exchanges
Address
3rd Floor, Building 20E, Units 303 and 305, Hong Kong Science Park, Shatin New Town, Hong Kong, HKG
OrbusNeich Medical Group Holdings Ltd is a China-based medical device maker of endovascular interventional instruments with majority reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich's majority revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.
Executives
Harmony Tree Limited 2101 Beneficial owner
Shenzhen Capital Group Co., Ltd. 2201 Interest of corporation controlled by you
Suzhou Red Earth Yeju Investment Ltd. 2101 Beneficial owner
Chien David 2201 Interest of corporation controlled by you
Lau Kwai Ching Denise 2201 Interest of corporation controlled by you
Shen Chuang Tou Zhi Zao Ye Zhuan Xing Sheng Ji Xin Cai Liao Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Shen Chuang Tou Hong Tu Si Mu Gu Quan Tou Zi Ji Jin Guan Li Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Hong Tu Ye Ju Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you

OrbusNeich Medical Group Holdings Headlines

No Headlines